Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...
Hosted on MSN19h
William Blair Initiates Coverage of Rubrik (RBRK) with Market Perform RecommendationFintel reports that on February 7, 2025, William Blair initiated coverage of Rubrik (NYSE:RBRK) with a Market Perform ...
Equities research analysts at William Blair upped their FY2025 EPS estimates for shares of Modine Manufacturing in a note ...
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...
William Blair initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating.Maximize Your Portfolio with Data Driven ...
William Blair initiated coverage of Rubrik (RBRK) with a Market Perform rating.Maximize Your Portfolio with Data Driven Insights:Leverage the ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...
William Blair International Growth Fund earns an Average Process Pillar rating. The predominant contributor to the rating is the fund's impressive long-term risk-adjusted performance. This can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback